Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93


Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma.

Park HC, Ahn JS, Yang DH, Jung SH, Oh IJ, Choi S, Lee SS, Kim MY, Kim YK, Kim HJ, Lee JJ.

Tuberc Respir Dis (Seoul). 2013 May;74(5):235-9. doi: 10.4046/trd.2013.74.5.235. Epub 2013 May 31.


Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.

Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA.

Cancer. 2001 Jul 15;92(2):207-17.


Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.

Tanosaki R, Okamoto S, Akatsuka N, Ishida A, Michikawa N, Masuda Y, Uchida H, Murata M, Kizaki M, Ikeda Y.

Cancer. 1994 Oct 1;74(7):1939-44.


EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer.

Repetto L, Biganzoli L, Koehne CH, Luebbe AS, Soubeyran P, Tjan-Heijnen VC, Aapro MS.

Eur J Cancer. 2003 Nov;39(16):2264-72. Review.


Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.

Sawada KI, Sato N, Kohno M, Hannda H, Yasukouchi T, Tanngo M, Hirayama A, Koike T.

Leuk Lymphoma. 1995 Dec;20(1-2):103-9.


Recombinant human granulocyte colony-stimulating factor infusion and/or autologous peripheral blood stem cell transplantation as a rescue for sequential high-dose combination chemotherapy: a preliminary report.

Chau WK, Lin CK, Chow MP, Wang SY, Liu JM, Ho CH, Chiu CF, Hsu HC, Tan TD, Chan WK, et al.

Zhonghua Yi Xue Za Zhi (Taipei). 1994 Nov;54(5):312-20.


Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.

Long GD, Negrin RS, Hoyle CF, Kusnierz-Glaz CR, Schriber JR, Blume KG, Chao NJ.

Cancer. 1995 Sep 1;76(5):860-8.


Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.

Stoppa AM, Bouabdallah R, Chabannon C, Novakovitch G, Vey N, Camerlo J, Blaise D, Xerri L, Resbeut M, Di Stefano D, Bardou VJ, Gastaut JA, Maraninchi D.

J Clin Oncol. 1997 May;15(5):1722-9.


Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Ann Oncol. 2003 Jun;14(6):881-93.


Interstitial pneumonitis related to granulocyte colony-stimulating factor administration following chemotherapy for elderly patients with non-Hodgkin's lymphoma.

Hasegawa Y, Ninomiya H, Kamoshita M, Ohtani K, Kobayashi T, Kojima H, Nagasawa T, Abe T.

Intern Med. 1997 May;36(5):360-4.


Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.

Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C.

J Clin Oncol. 1998 Jul;16(7):2352-8.


Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma.

Katsuya H, Suzumiya J, Sasaki H, Ishitsuka K, Shibata T, Takamatsu Y, Tamura K.

Leuk Lymphoma. 2009 Nov;50(11):1818-23. doi: 10.3109/10428190903258780.


Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.

Avilés A, Díaz-Maqueo JC, Talavera A, Nambo MJ, García EL.

Leuk Lymphoma. 1994 Sep;15(1-2):153-7.


High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma.

Hyun SY, Cheong JW, Kim SJ, Min YH, Yang DH, Ahn JS, Lee WS, Ryoo HM, Do YR, Lee HS, Lee JH, Oh SY, Suh C, Yhim HY, Kim JS.

Biol Blood Marrow Transplant. 2014 Jan;20(1):73-9. doi: 10.1016/j.bbmt.2013.10.012. Epub 2013 Oct 17.


Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.

Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, Chou T, Aikawa K, Uike N, Mizorogi F, Ohno T, Ikeda S, Sai T, Taniwaki M, Kawano F, Niimi M, Hotta T, Shimoyama M, Tobinai K; Members of the lymphoma study group of the Japan Clinical Oncology Group (JCOG).

Ann Oncol. 2002 Sep;13(9):1347-55.


Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, et al.

N Engl J Med. 1991 Jul 18;325(3):164-70.

Supplemental Content

Support Center